Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT05798208 |
| Other study ID # |
IR.SUMS.MED.REC.1401 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
February 15, 2020 |
| Est. completion date |
February 20, 2023 |
Study information
| Verified date |
April 2023 |
| Source |
Shiraz University of Medical Sciences |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
In this single center , retrospective study, 5355 covid patient were selected from 2020 to
2022, with recorded blood pressure before covid and recording after covid. Blood pressure
before and after covid were compared, by pair T test.
Description:
design and participants This single-center retrospective cohort study was conducted at an
outpatient cardiology clinic in Shiraz, Iran, between February 15, 2020, and December 28,
2022. We evaluated patients with a confirmed diagnosis of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection by RNA reverse-transcriptase polymerase-chain-reaction
assays from nasopharyngeal or oropharyngeal swab specimens according to World Health
Organization guidelines (12). Two physicians (PA, MY) reviewed the patients' electronic
medical records, including demographics, comorbidities, vital signs, treatments, and
outcomes. Ambiguities were resolved by a third author (MM).
The current study included all COVID-19 patients who had at least one documented blood
pressure measurement in the three months preceding infection and one documented measurement
one to three months following recovery. The following patients were excluded: those under 18,
with hospital admission due to COVID-19, who received corticosteroid therapy, those with a
history of systemic inflammatory disease, kidney or liver, immunocompromised patients, and
those who switched their antihypertensive regimen during the study. Finally, 5,355 eligible
patients were investigated . The primary outcome was to assess BP variation following
infection (particularly a prolonged rise in BP) among non-hospitalized COVID-19 patients. The
secondary outcome was to identify the predictor factors of BP variation.
The present study was approved by the Ethics Committee of Shiraz University of Medical
Sciences under code IR.SUMS.MED.REC.1401.465 , and the need for informed consent was waived
due to the study's retrospective nature and the absence of patient identifiers in the
presented data.
